港股異動 | 復星醫藥AH齊挫 子公司獲授權生產默克新冠口服藥 但非獨家許可、未獲採購訂單
格隆匯1月24日丨復星醫藥(02196.HK)跌逾5%,報34.65港元;復星醫藥(600196.SH)更是大跌7.45%。藥品專利池組織(MPP)與27家企業簽署授權生產默克研發新冠治療口服藥物Molnupiravir,當中包括復星醫藥。復星醫藥週日在港交所公吿稱,旗下子企獲授權複制默沙東Molnupiravir,只限在105箇中低收入國家或地區使用相關專利和專有技術,而且定價會較低,強調有關協議不是獨家許可,集團就合作藥物尚無在手訂單,尚未開展相關生產。復星強調,協議下公司新冠治療口服藥物Molnupiravir開展生產、商業化及相關權利,只包括印度、巴基斯坦、科特迪瓦等較低收入地區,當中不包括中國。集團表示,合作藥物在區域內能否獲得當地藥品監管機構上市批准,或藥物上市時間仍不確定,但預計在該分許可下該藥物的定價將會低於中高收入國家的售價,而且當新冠疫情不再被世衞列為“國際關注的突發公共衞生事件”,將會按年度淨銷售額的5%或10%向默克支付專利使用費。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.